Work

Impact of a Novel Dietary Supplement on Efficacy of Pharmacological Treatments for Androgenic Alopecia: A Real‐Life, Multicenter, Randomized, Assessor‐Blinded Trial on 225 Subjects

Year: 2025

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Abstract: BACKGROUND: Minoxidil and finasteride are currently the only FDA-approved pharmacological treatments for androgenic alopecia (AGA) and female androgenic alopecia (FAGA). However, substantial improvement is observed in no more than 20% of patients in the medium term. To enhance clinical responses, nonpharmacological dietary supplementation is often utilized. AIMS: This study evaluated the efficacy of a novel dietary supplement, AGA-P, which contains Serenoa repens extract, Cucurbita pepo extract, L-Cystine, and Vitamin C, in a multicenter, randomized, assessor-blinded, real-life trial alongside pharmacological treatments. The objective was to determine whether dietary supplementation could improve the clinical efficacy of minoxidil and finasteride. PATIENTS AND METHODS: A total of 225 subjects with AGA or FAGA (165 men, mean age 40 ± 14 years, range 18-74) were enrolled after obtaining informed consent. Inclusion criteria included male subjects over 18 years and postmenopausal women with mild to moderate AGA/FAGA, eligible for dietary and/or pharmacological treatment. Of these participants, 106 (24 women and 82 men) were assigned to receive pharmacological treatment plus dietary supplementation (one capsule daily; Group A), while 119 (36 women and 83 men) received drug treatment only (Group B). The pharmacological treatments consisted of topical minoxidil and oral finasteride in most cases. Treatment duration was 6 months. RESULTS: The results indicated that oral supplementation significantly increased the clinical efficacy of pharmacological treatments for mild-to-severe AGA/FAGA compared to drug treatment alone (great improvement: Group A 36.5% vs. Group B 25%; p = 0.04). CONCLUSION: Oral supplementation of AGA-P significantly increases the clinical efficacy of pharmacological treatments for mild-to-severe AGA/FAGA (Study Registration: ISRCTN-19671217).

Source: Journal of Cosmetic Dermatology

DOI: 10.1111/jocd.70388

Authors: Massimo Milani, Stefano Alfano, The AGA‐P Real‐Life Study Group

Institution: Difa Cooper (Italy)

Language: English

Topic: Hair Growth and Disorders

Subfield: Urology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,020